
Erratum

Erratum to: Systematic Verification of Bioanalytical Similarity Between a Biosimilar and a Reference Biotherapeutic: Committee Recommendations for the Development and Validation of a Single Ligand-Binding Assay to Support Pharmacokinetic Assessments

Joseph C. Marini,^{1,11} Michael Anderson,² Xiao-Yan Cai,³ John Chappell,⁴ Todd Coffey,⁵ Dominique Gouty,⁶ Aparna Kasinath,⁷ Vera Koppenburg,⁸ Philip Oldfield,⁹ Shannon Rebarchak,¹ and Ronald R. Bowsher¹⁰

published online 3 April 2017

Erratum to: AAPS J

DOI: 10.1208/s12248-014-9669-5

There is a slight error in files Supplemental 1 and Supplemental 2 for the article published in November 2014, Volume 16, Issue 6, pp 1149-1158.

The error is in the Summary tab in the Excel files.

- For the “90% Upper CI” (Column K), cells K3-K7 should reference cell N41 in QC tabs 1-5.
- For the “90% Upper CI” (Column L), cells L3-L7 should reference cell N42 in QC tabs 1-5.

The online version of the original article can be found at <http://dx.doi.org/10.1208/s12248-014-9669-5>.

¹ Janssen Research and Development, LLC, 1400 McKean Road, PO Box 1776, Spring House, PA 19477, USA.

² BDS Immunoassay Services, Tampa, FL, USA.

³ Merck & Company, Inc, Union, NJ, USA.

⁴ CPR Pharma Services Pty Ltd, Thebarton, South Australia, Australia.

⁵ CMC Biostatistics, LLC, Snohomish, WA, USA.

⁶ BioAgilytix Labs, Durham, NC, USA.

⁷ Clinigene International Limited, Bangalore, India.

⁸ Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany.

⁹ Philip Oldfield Bioanalytical Consulting, Hudson, Quebec, Canada.

¹⁰ B2S Consulting, Indianapolis, IN, USA.

¹¹ To whom correspondence should be addressed. (e-mail: jmarini@its.jnj.com)